Cancer Supportive Care Drugs Market Update 2024: Expected to Exhibit USD 25 Billion Revenue by 2032, Claims AMR
The Cancer Supportive Care Drugs Market Landscape:
According to a new report published by Allied Market Research, titled, “Cancer Supportive Care Drugs Market,” The cancer supportive care drugs market was valued at $20.4 billion in 2022, and is estimated to reach $25 billion by 2032, growing at a CAGR of 2% from 2023 to 2032.
The expansion of healthcare infrastructure, increasing incidence of cancer cases, and growing awareness about the benefits of cancer supportive medications are driving factors behind the global cancer supportive drugs market’s growth. However, advancements in targeted cancer therapy pose a challenge to market expansion. Conversely, the anticipated rise in healthcare expansion is poised to create lucrative opportunities for the cancer supportive drugs market in the forecast period.
Report Coverage & Details:
| Report Coverage | Details |
| Forecast Period | 2023–2032 |
| Base Year | 2022 |
| Market Size In 2022 | $20.3 Billion |
| Market Size In 2032 | $24.9 Billion |
| CAGR | 2.03% |
| No. Of Pages In Report | 334 |
| Segments Covered | Type, Application, Distribution Channel, And Region |
| Drivers | Rise In Prevalence Of Cancer And Adverse Effects Associated With Use Of Cancer Drugs. |
| Increase In Adoption Of Cancer Supportive Care Drugs. | |
| Growth In Geriatric Population. | |
| Opportunities | Increase In R&D And Number Of Pipeline Cancer Supportive Care Drugs. |
| Restraints | Advancements In Targeted Therapy For Cancer |
Recession Scenario
- In times of economic recession, the healthcare sector, including cancer supportive drugs, may face notable impacts. Economic downturns could impede investment in research and development.
- However, the increasing prevalence of cancer cases and heightened attention to post-cancer treatment care may stimulate interest in cancer supportive drugs.
For Procurement Information – https://www.alliedmarketresearch.com/purchase-enquiry/A07133
Regional Analysis
North America dominated the global cancer supportive drugs market in 2022, capturing nearly half of the revenue due to its strong healthcare infrastructure, high cancer rates, advanced treatment options, and focus on patient outcomes. However, the Asia-Pacific region is expected to witness the highest growth rate (2.81% CAGR) during the forecast period, driven by its large population, growing healthcare awareness, and rising cancer incidence, leading to increased demand for supportive care drugs.
Key findings of the study
- On the basis of type, the granulocyte colony-stimulating factors (G-CSFs) segment dominated the cancer supportive care drugs industry in terms of revenue in 2022. However, the antiemetics segment is anticipated to grow at the fastest CAGR during the forecast period.
- On the basis of type, the breast cancer segment dominated the cancer supportive care drugs industry in terms of revenue in 2022. However, the lung cancer segment is anticipated to grow at the fastest CAGR during the forecast period.
- On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2022. However, the online providers segment is anticipated to grow at the fastest CAGR during the forecast period.
- Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Leading Market Players:
- Novartis AG
- Johnson & Johnson
- Amgen Inc.
- Baxter International Inc.
- F. Hoffmann-la Roche AG
- Helsinn Healthcare SA
- Heron Therapeutics, Inc.
- Merck And Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
Recent Developments in the Cancer Supportive Care Drugs Industry
Recent Agreement in Cancer Supportive Care Drugs Market
- In January 2023, Helsinn Group, and Immedica Pharma AB, a pharmaceutical company focused on the commercialization of rare and specialty care products, announced that they have entered an exclusive long-term license and distribution agreement for two cancer supportive care products indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in core European markets: AKYNZEO (Netupitant-Palonosetron fixed combination) and ALOXI (Palonosetron).
- In December 2020, McKesson and Amgen Inc., one of the world’s leading biotechnology companies, have signed a strategic agreement to help improve cancer care in community oncology settings. This multi-year agreement bridges the power and reach of the two companies and will focus on reducing gaps in care by optimizing access to innovative precision medicine and immuno-oncology in the community setting.
Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/A07133
Recent Product Approval in Cancer Supportive Care Drugs Market
- In November 2020, Pfizer Inc. announced that the European Commission (EC) has approved NYVEPRIA (pegfilgrastim). It is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (except for chronic myeloid leukemia and myelodysplastic syndromes).
Cancer Supportive Care Drugs Market Segmentation
| By Type |
|
| By Application |
|
| By Distribution Channel |
|
| By Region |
|
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer supportive care drugs market analysis from 2022 to 2032 to identify the prevailing cancer supportive care drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the cancer supportive care drugs industry segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global cancer supportive care drugs market trends, key players, market segments, application areas, and market growth strategies.
Comprehensive Healthcare Industry Research Studies: –
Plasma Protein Therapeutics Market https://www.alliedmarketresearch.com/plasma-protein-therapeutics-market-A12692
Intrapartum Monitoring Devices Market https://www.alliedmarketresearch.com/intrapartum-monitoring-devices-market-A10998
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Editor Details
-
Company:
- The Wire Times
